Introduction
Colorectal cancer (CRC) is the most common malignancy worldwide. CRC has been considered to develop through a gradual series of histological changes of adenomatous polyps, called 'adenoma-carcinoma' sequence. Intestinal adenomatous polyps are thus believed to be major precursors of CRC. Epidemiologic studies indicate that almost half of the population will develop at least one benign adenomatous colonic polyp during life, with 3% of those cases going on to develop colorectal cancers (1) . Further studies indicated that the mutations of adenomatous polyposis coli (APC) gene are responsible for the development of colorectal cancer in all familial adenomatous polyposis (FAP) cases and in 59% of sporadic colorectal cancer cases (2) . Mutation of APC gene will cause the dysregulation of the Wnt/β-catenin signaling pathway in which accumulate high levels of β-catenin in nucleus and then lead to the transcription of many cell proliferation-related genes (3) . Currently, a combination of surgery and chemotherapy is used to treat colon cancers. The 5-year survival expectation for CRC patients ranges from 93% for early stages to 8% in fully advanced stages. Unfortunately, only about 37% of patients are diagnosed at early stage (4) . Thus, the chemoprevention regimen seems to be an attractive option for early stage of CRC.
Several drugs have been studied in this field. There is considerable evidence that nonsteroidal antiinflammatory drugs (NSAIDs), particularly aspirin, could reduce the risk of intestinal adenomatous polyps (5) . The epidemiologic reports determined the anticarcinogenic effects of aspirin in high-risk population of CRC (6) . Clinical trials in patients with familial adenomatous polyposis showed that aspirin might reduce the risk of CRC through regression of intestinal adenomatous polyps (7) . These studies suggested that aspirin might prevent adenocarcinoma growth through the mechanism of anti-inflammatory activity, e.g. the activities of COX-2 and 5-LOX (8) . However, longterm use of aspirin is not free from toxicities. Some studies indicated that the risk-benefit profiles of aspirin for prevention of CRC are insufficient and no definitive recommendations can be made (9) .
Boswellic acids (BAs) were a mixture of pentacyclic triterpene acids which isolated from the gum resin of Boswellia serrata (10) . BAs have been used as anti-inflammation agents for the treatment of many diseases, such as chronic colitis, ulcerative colitis and osteoarthritis (11) . Acetyl-11-keto-beta-BA (AKBA) is one of these BAs which have been considered to be most effective among these BAs. In our previous study, we found that AKBA by p.o. gavage prevented the formation of intestinal adenomatous polyposis in APC Min/+ mice. AKBA might exert its chemopreventive action through multiple mechanisms including antiproliferation, apoptosis induction, anti-inflammation and anti-angiogenesis (12) . In this study, we compared these effects of AKBA with that of aspirin in the prevention of intestinal adenomatous polyposis in APC Min/+ mice.
Materials and Methods

Drugs
AKBA was purchased from Sigma-Aldrich (A9855). The purity of AKBA was 99.5%. Aspirin (A5376) was also purchased from Sigma-Aldrich with ≥ 99.0% purity. AKBA and aspirin were both suspended in 0.5% sodium carboxymethyl cellulose (CMC) in sterile water before application. (12) . A total of 18 male mice (age, 4 weeks) were randomly divided into three groups. After one week of acclimation, the mice were administrated with the vehicle control (0.5% CMC, w/ v), AKBA 80 mg/kg and aspirin 80 mg/kg. Drugs and vehicle were given by p.o. gavage daily (0.2 mL/10 g body weight) for 7 consecutive weeks. Mice were weighed weekly and observed daily for any signs of toxicity. This research protocol was approved by the Animal Care and Use Committee at Shandong University.
Quantification of macroscopic and microscopic intestinal adenomatous polyp
Mice were sacrificed by anesthetizing. After sacrifice, the whole intestine including small intestine and colon were removed from each mouse. The intestines were spread onto filter paper, opened longitudinally with fine scissors, and washed with saline. Adenomatous polyps on the intestines were counted, and their sizes were measured under a dissecting microscope. After counting, the intestines were fixed in formalin, embedded in paraffin and stained with hematoxylin and eosin for further examination.
Immunohistochemistry staining assay
Immunohistochemistry staining assay was performed to analyze the expressions of β-catenin, cyclin D1, cyclooxygenase-2 (COX-2), and 5-LOX in the adenomatous polyps. Paraffin-embedded sections (4 μm thick) were cut from formalin-fixed intestinal adenomatous polyps. After deparaffinization, the immunohistochemistry staining assay was carried out as described previously (12, 13) . The primary antibodies included β-catenin (9562), COX-2 (4842), cyclin D1 (2922, Cell Signaling), 5-LOX (bs-0526R, Bioss, China). Second antibodies included anti-mouse IgG and anti-rabbit IgG (Santa Cruz).
The effects of AKBA or aspirin on the growth of adenomatous polyps were estimated by determining the levels of these proteins in adenomatous polyps. Positive staining with cyclin D1 was defined as brown staining in nuclei of adenomatous cells. The percentage of positive cells was calculated as described previously (14) . Positive staining with COX-2 and 5-LOX was determined based on brown intensity in membrane, cytoplasm and nucleus of adenomatous cells (15) . β-Catenin is a dynamic protein enriched in the membrane of normal cells and enters the nucleus and cytoplasm of adenomatous cells (16) . We determined the brown intensity of β-catenin in the cytoplasm and nucleus of adenomatous cells. The levels of these
Results
General observation
During the course of study, AKBA and aspirin were well tolerated by mice. There was no significant difference in body weight, peripheral blood element counts and other biological signs between AKBA or aspirin -treated and the vehicle control mice (data not shown)..
Prevention of intestinal adenomatous polyp formation by AKBA or aspirin
At age of 12 weeks, the number of adenomatous polyps in small intestine and colon of control mice were 29.0 ± 2.9 and 5.8 ± 1.0, respectively. Both AKBA and aspirin were found to have the activity against adenomatous polyp formation, whereas, AKBA's activity was more potently than aspirin. As shown in Figures 1A Figures 1A and 1B) .
The different efficacy of AKBA and aspirin was also observed by measuring the size of these adenomatous polyps. We divided the intestinal adenomatous polyps into four groups by small (< 1 mm), medium (1-2 mm), large (2-3 mm), and super large polyps (> 3 mm). In proteins were quantified by scoring the intensity as 0 (no staining), +1 (very weak), +2 (weak), +3 (moderate), and +4 (strong) in five randomly selected fields at 400× magnification in each sample (12).
TUNEL staining assay
The apoptotic cells in intestinal adenomatous polyps were determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining using an in situ cell death detection kit (Roche, Germany). Serial 4-μm sections of intestinal adenomatous polyps were prepared and the staining was performed according to manufacturer's instructions. Adenomatous cells with brown-stained nuclei were recognized as TUNEL positive (12) . The proportion of apoptotic cells in 6 mice was scored in randomly chosen fields under a microscope.
Western blotting assay
Western blotting assay was performed to determine the expressions of proteins-related to tumorigenesis in intestinal adenomatous polyps. Adenomatous polyps were incubated with 50 μL RIPA lysis buffer at 4°C for 30 min and then the lysates (30 μg of protein per lane) were fractionated by SDS-PAGE. The proteins were electro-transferred onto PVDF membranes and detected using the primary antibodies as described previously (17) . The primary antibodies included those specific for NF-kB (sc-8008), p-NF-kB Ser 536 (sc-33020), TOPO IIβ (sc-25330, Santa Cruz), caspase-3 (9662), caspase-9 (9502), β-catenin (9562), COX-2 (4842), cyclin D1 (2922), p-c-Jun (3270), survivin (2808), cleaved PARP (9541), PCNA (2586), β-actin (5779-1, Cell Signaling), Wnt-2 (3169-1, Epitomics) and c-Myc (ab32072, Abcam). The PVDF membranes were washed in 0.05% Tween-20/TBS and then incubated with horseradish peroxidase-conjugated secondary antibody. The bound antibodies were visualized using an enhanced chemiluminescence reagent (Millipore) and quantified by densitometry using ChemiDoc XRS+ image analyzer (Bio-Rad). Densitometric analyses of bands were adjusted with β-actin as loading control.
Statistical analysis
Data were described as mean ± S.D. Statistical analysis was done with SPSS/Win13.0 software (SPSS, Inc., Chicago, Illinois). Comparisons between APC Min/+ control and AKBA-treated mice were conducted by two-tailed Student's t test. Comparison multiple groups were analyzed by one-way ANOVA and multiple between-group comparisons were performed using the S-N-K method. A p value less than 0.05 was considered statistically significant. this study, we did not find super large polyps in small intestines. As shown in Figure 1C, (Figure 1 D) . A significant difference existed between these two groups of data from AKBA-and aspirin-treated mice (p < 0.05).
AKBA exhibited more potential than aspirin in prevention of tumorigenesis and malignant progression of intestinal polyps
We examined the intestinal polyps by histopathologic analysis. Both AKBA and aspirin possessed the activity against tumorigenesis and malignant progression of intestinal polyps. In APC Min/+ mice, small intestinal polyps were determined to be adenomas, showing the crowded pencil-shaped hyperchromatic nuclei with preserved polarity and diminished mucin (Figure 2A) . In colonic polyps, larger polyps were determined to be advanced adenomas, showing focal high grade dysplasia and intramucosal carcinomas demonstrated marked nuclear pleopmorphism with lack of nuclear polarity ( Figure 2B ). The number of dysplastic cells and degree of dysplasia in each polyp was obviously reduced in the AKBA-treated mice ( Figure 2C ). High grade dysplasia or intramucosal carcinoma was not found in the AKBAtreated polyps. The interdigitated normal appearing intestinal villi were observed in these intestinal polyps ( Figure 2C ). AKBA' effect, i.e. the decrease of polyp size and degree of dysplasia, was more prominent in the colonic polyps ( Figure 2D ). Aspirin also showed the effect of prevention tumorigenesis in small intestinal polyps and colonic polyps, whereas, its effect was not as well as AKBA in the prevention of intestinal tumorigenesis and malignant progression ( Figures 2E  and 2F ).
AKBA had greater effect than aspirin in induction of apoptosis in intestinal adenocarcinomas
Examination of intestinal polyps by TUNEL staining assay indicated the apoptotic effect of AKBA and aspirin on adenocarcinomas. As shown in Figure 3A , AKBA strongly increased the number of TUNEL-positive cells by 269.7% (p < 0.01 vs. untreated control) in small intestinal polyps and 252.5% (p < 0.01 vs. the vehicle control) in colonic polyps. Aspirin increased TUNEL staining cells by 56.6% (p < 0.05 vs. the vehicle control), in small intestinal polyps, and by 54.2% (p < 0.05 vs. the vehicle control), in colonic polyps. A significant difference existed between AKBA and aspirin (p < 0.05).
Further analysis by western blotting assay suggested that these effects by AKBA might arise from its role of modulating the apoptotic-related proteins. As shown in Figure 3B , the levels of Topo IIIβ and PCNA in the AKBA-treated adenomatous polyps were significantly reduced by 54.7% (p < 0.01 vs. the vehicle control), 68.7% (p < 0.01 vs. vehicle control), respectively, in small intestinal polyps; by 72.7% (p < 0.01 vs. the vehicle control), 55.3% (p < 0.01 vs. the vehicle control), 
×200). (E):
The small intestine in the aspirin-treated mice (×100). e' (inset): part of crypt architectures were in their normal shape with unremarkable nuclei (×200). (F): Colon in the aspirin-treated mice (×100). f' (inset): some of the structure and nuclei of epithelium were in normal shape, whereas not as well as in the AKBA-treated colons (×200).
respectively, in colonic polyps. Aspirin reduced the level of Topo IIβ and PCNA by 41.6% (p < 0.05 vs. the vehicle control), 40.8% (p < 0.01 vs. the vehicle control), respectively, in small intestinal polyps and by 55.0% (p < 0.01 vs. the vehicle control), 30.1% (p < 0.05 vs. the vehicle control), respectively, in colonic polyps. Analysis of caspase-9, caspase-3, and cleaved PARP in the adenomatous polyps confirmed the AKBA's activity. As shown in Figure 3C , the levels of caspase-9, caspase-3, and survivin in the AKBA-treated polyps were significantly reduced by 65 
Modulation of the Wnt/β-catenin signaling pathway by AKBA
The expression levels of proteins in the Wnt/β-catenin signaling pathway were determined by the assays of immunochemical staining and western blotting. AKBA possessed the activity of modulating the Wnt/β-catenin pathway, whereas, aspirin did not significantly affect these proteins in this signaling pathway. In the AKBAtreated polyps, the level of β-catenin was strongly reduced by 49.0% (p < 0.01 vs. the vehicle control) in small intestinal polyps, by 46.8% (p < 0.01 vs. the vehicle control) in colonic polyps ( Figure 4A ). The level of cyclin D1 was significantly reduced by 54.9% (p < 0.05 vs. the vehicle control) in small intestinal polyps, and by 50.6% (p < 0.01 vs. the vehicle control) in colonic polyps, respectively ( Figure 4B ).
Western blotting assay further determined the levels of proteins in the Wnt/β-catenin signaling pathway and its downstream targets. In the AKBA-treated adenomatous polyps, the levels of Wnt-2 and β-catenin were significantly reduced by 33.1% (p < 0.05 vs. the vehicle control) and 35.7% (p < 0.05 vs. the vehicle control), respectively, in small intestinal polyps, and 41.2% (p < 0.01 vs. the vehicle control) and 34.4% (p < 0.01 vs. the vehicle control), respectively, in colonic polyps ( Figure 4C ). Figure 4D showed the levels of the downstream targets of the Wnt/β-catenin pathway. In the AKBA-treated adenomatous polyps, the levels of cyclin D1, c-Myc and p-c-jun were significantly decreased by 34.4% (p < 0.05 vs. the vehicle control), 41.8% (p < 0.01 vs. the vehicle control), 53.3% (p < 0.01 vs. the vehicle control), respectively, in small intestine polyps; by 40.5 % (p < 0.01 vs. the vehicle control), 78.0% (p < 0.01 vs. the vehicle control), and 49.8% (p < 0.01 vs. the vehicle control), respectively, in colonic polyps. The levels of these proteins did not show significant changes in the aspirin-treated adenomatous polyps both in small intestines and colons (p > 0.05 vs. the vehicle control).
AKBA had a great effect on suppression of inflammatory factors
We evaluated the inhibitory effect of AKBA in the suppression of inflammatory cytokines in adenomatous polyps. Immunochemical staining showed that both AKBA and aspirin possessed the activity of inhibition on COX-2, and 5-LOX expression ( Figures 5A and 5B) . We compared the density of immunochemical staining of COX-2 and 5-LOX in these adenomatous polyps. A greater inhibitory effect of AKBA on these inflammatory cytokines was observed as compared to that of aspirin (p < 0.05). Similar profiles of the inhibitory effect on these cytokines were also determined in the AKBAand aspirin-treated adenomatous polyps as evaluated by western blotting assay ( Figure 5C ). As shown in Figure 5D , the levels of p-NF-κBSer 536 and NF-κB in the adenomatous polyps by AKBA were significantly reduced by 51.6% (p < 0.01 vs. the vehicle control), 42.5% (p < 0.01 vs. the vehicle control), respectively, in small intestines; by 74.4% (p < 0.01 vs. the vehicle control), 52.3% (p < 0.01 vs. the vehicle control), in colons. The levels of p-NF-κBSer 536 and NF-κB in the aspirin-treated adenomatous polyps were reduced by 31.4% (p < 0.05 vs. the vehicle control), 22.2% (p < 0.05 vs. the vehicle control), respectively, in small intestines and 57.2% (p < 0.01 vs. the vehicle control), 42.6% (p < 0.01 vs. the vehicle control), respectively, in colons. These results indicated that AKBA possessed greater activity than aspirin in the suppression these inflammatory stimuli in intestinal adenomatous polyps.
Discussion
AKBA, a naturally occurring, orally active pentacyclic triterpenoid extracted from boswellia serrata, was initially determined for its anti-inflammatory properties and used for the treatment of many chronic inflammation diseases (18) . Recent studies have highlighted its role in anti-cancer properties. AKBA by oral administration in mice could change intestinal microenvironment, prevent stroma and epithelial cell growth (12) . In this study, we determined the inhibitory effect of AKBA in the adenomatous polyposis coli multiple intestinal neoplasia (APC Min/+ ) mouse model and then compared these results with those of aspirin. AKBA was found to have higher efficacy than aspirin in the prevention of intestinal adenomatous polyposis development. Our statistical analysis suggested that the inhibitory effect of AKBA might arise from its multiple actions including anti-proliferation, induction of apoptosis, modulation of the Wnt/β-catenin signaling pathway, and anti-inflammation. These results supported our previous results that AKBA could develop as a promising agent for the prevention of intestinal tumorigenesis (12) .
The development of intestinal tumorigenesis is a gradual series of histological changes, called the 'adenomatous polyps-carcinoma' sequence. This sequence has been mostly considered to arise from the mutation of adenomatous polyposis coli (APC) gene (19) . In the APC Min/+ mouse model, the mutation of APC gene leads to the dysregulation of the Wnt/ β-catenin signaling pathway in which accumulated β-catenin in nucleus leads to transcription of many its target genes. These target genes are amplified following the activation of the aberrant Wnt/β-catenin signaling pathway (20, 21) . Among the targets of β-catenin, PCNA is a marker of cell proliferation and is highly expressed during the 'adenomatous polyps-carcinoma' sequence. Cyclin D1 is a cell cycle protein frequently overexpressed in adenomatous polyps. A high level of c-Myc stimulates cell proliferation and prevents apoptosis in adenomatous polyps. c-Myc and cyclin D1 have also been identified as the transactivation targets of the β-catenin-TCF complex through binding site in their promoter region. Survivin is a prominent antiapoptotic molecule widely expressed in adenomatous cells. Overexpression of survivin could lead to adenomatous proliferation (22, 23) . The APC Min/+ mouse model is thus widely used for evaluation of chemopreventive agents. AKBA possessed strong activity of modulating the Wnt/β-catenin pathway and many of its target proteins, including cyclin D, PCNA, survivin, c-Myc, and p-c-jun. In this study, we did not find significant changes of proteins in Wnt/β-catenin pathway in the aspirin-treated adenomatous polyps. We thus suggested that AKBA might be an inhibitor of the Wnt/β-catenin signaling pathway.
In colonic adenocarcinomas, the inflammatory microenvironment is characterized by the presence of inflammatory stimuli including cytokines and network of growth factors both supporting stroma and adenomatous areas (24, 25) . These stimuli contribute to adenocarcinoma expansion, and even facilitate the metastatic process. Important inflammatory stimuli include COX-2, NF-κB, 5-LOX, PGEs, LTB4, IL-6, TNF-α, FGF-2, and iNOS etc. (12, 26) . NF-κB is considered as a 'first responder' to various types of cellular stress. NF-κB activation could induce IκB phosphorylation, targeting it for degradation through an ubiquitin-proteasome pathway, releasing NF-κB to enter the nucleus, where it regulates gene expression. COX-2 is an immediate-early growth response gene product. In response to stimulation of these cytokines, the intercellular communications of the NF-κB-COX-2 pathway take place and lead to adenocarcinoma growth. The accumulation of these molecules further stimulates the Wnt/β-catenin signaling pathway, leading to expansion of adenomatous polyps (27) . 5-LOX is a key enzyme in metabolizing arachidonic acid to leukotrienes which act quickly to promote the progression of intestinal polyps through activation of NF-κB. High levels of 5-LOX directly stimulate angiogenesis, proliferation and anti-apoptosis in adenomatous polyps (26) . In addition, COX-2 and 5-LOX are usually co-expressed and up-regulated in the intestinal adenomatous polyps (12) . Aspirin has long been considered to have the activity of antiinflammation through the mechanisms of suppressing COX-2 and prostaglandin E2 (PGE2) (5, 6) . Recent studies suggested that aspirin might possess the activity against intestinal adenocarcinomas. The mechanism of aspirin action has been considered to be associated with its anti-inflammation activity. In this study, we compared the efficacy and mechanisms of AKBA with those of aspirin. AKBA possessed a greater activity than aspirin in the suppression of these inflammatory cytokines. These findings suggest that administration of AKBA might have a more beneficial effect than aspirin in prevention of colon adenocarcinoma growth.
In conclusion, AKBA significantly prevented the formation of intestinal adenomatous polyposis without toxicity to mice. Our comparative study suggested that AKBA possess more potential than aspirin in antiproliferation, induction of apoptosis, modulation of the Wnt/β-catenin pathway, and anti-inflammation. These results support our previous results that AKBA could develop as a promising agent in prevention of colorectal adenocarcinomas.
